



Results for announcement to the market		
Name of issuer	Ryman Healthcare Limited	
Reporting Period	12 months to 31 March 2025	
Previous Reporting Period	12 months to 31 March 2024	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$760,695	10.26%
Total Revenue	\$760,695	10.26%
Net profit/(loss) from continuing operations	\$(436,831)	157.47%
Total net profit/(loss)	\$(436,831)	157.47%
Interim/Final Dividend		
Amount per Quoted Equity Security	No dividend is to be paid for the 12 months ended 31 March 2025.	
Imputed amount per Quoted Equity Security	N/A	
Record Date	N/A	
Dividend Payment Date	N/A	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security (in dollars and cents per security)	\$4.182	\$5.011 (restated)
A brief explanation of any of the figures above necessary to enable the figures to be understood	Prior comparative periods have been restated to align with changes to the Group's financial reporting. Refer to note 1 of the Consolidated Financial Statements for explanation	
Authority for this announcement		
Name of person authorised to make this announcement	Morgan Powell	
Contact person for this announcement	Rob Woodgate	
Contact phone number	+64 3 366 4069	
Contact email address	rob.woodgate@rymanhealthcare.com	
Date of release through MAP	29 May 2025	

Audited financial statements accompany this announcement.